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Abstract 
lnterpatient variabiff1y among medication doses has been a long-
standing obstacle tor many prescribers. Some medications result in 
increased morbidity and mortalffy in a small percentage of the popu-
lation. For many years, the cause of such toxicities was unknown. 
This myslery has been resolved by the discovery that the absence or 
abnormaflty of specific genes that code for receptors, drug-targeted 
proteins, drug transport mechanisms and drug metabolizing en-
zymes could alter how an affected individual will respond to a given 
drug. One such incidence is the genetic polymorphism in thiopurine 
s-methyftranferase (TPMT). In comprehending the mechanism of 
this polymorphism, it is important to understand the metabolic path-
way of thiopurine drugs. Through study of this pathway, researchers 
began to look into whether other polymorphisms aside from TPMT 
could be a source of the dose-rsiated toxicity with the thiopurlnes. 
The prospect that this polymorphism may contribu1e to an increase 
in number or exacerbation of side effects beyond the commonly pre-
sented bone marrow toxicitv also has been visited. Becoming more 
aware of this genetic issue has presented the need to evaluate the 
cost eifecttveness of genetic testing to counteract the expectOO cost 
of treating extreme myelosuppression. Havtng knowledge of new 
ptlamlacogenomic technology and the tests avattable can benefH 
pharmacists in any setting. Pharmacists will be more prepared to 
address patient concerns such as necessity and cost effectiveness. 
Introduction 
Recently, opinion articles were published in the New England Journal of 
Medicine that discussed the controversies surrounding genetic testing 
and, in particular, the marketing of this testing directly to consumers.1•2 
As pharmacists, we must be aware of these advances as we enter into 
the "genomic" age and how they may impact our patients. In this article, 
we present a case study of thiopurine s-methytransferase polymorphism. 
Ten to 28 percent of patients receiving azothioprine or mercaptopurine 
therapy experience toxicity that requires stopping treatment or, in severe 
cases, results in death.3 Recognizing that this well-known occurrence 
is related to a genetic polymorphism in thiopurine s-methyltranferase 
(TPMT) has provided insights into the mechanism of intolerance and 
offered strategies to avoid these toxicities. 
Numerous medications exhibit wide interpatient variability in efficacy and 
toxicity. Although nongenetic factors influence the effects of medica-
tions, the variability in response is many times due to single nucleotide 
polymorphisms (SNPs) in genes encoding drug-metabolizing enzymes, 
drug transporters and/or drug targets. Initial reports from the human 
genome project described over 1.4 million SNPs in the genome, but this 
number continues to grow with extended research.4 There are more than 
30 families of drug-metabolizing enzymes in humans, all with genetic 
variants causing the translation of such proteins to result in functional 
differences. Patients who inherit a drug-metabolizing enzyme deficiency 
must be treated with markedly different doses of the affected medica-
tions. Therefore, identifying genetic determinants of drug response can 
help optimize the selection of drug therapy. 
TPMT polymorphism 
One of the most understood examples of a genetic polymorphism 
is that of TPMT, which catalyzes the s-methylation of azathioprine, 
mercaptopurine and thioguanine.4 These medications, together called 
the thiopurine drugs, are widely used in the treatment of leukemia, 
inflammatory bowel diseases and severe rhematic diseases and for 
immunosuppression following solid organ transplantation.3 Azathioprine, 
mercaptopurine and thiogunanine are all inactive prodrugs requiring 
activation to thiopurine nucleotides. The active nucleotides compete with 
endogenous nucleotides in many biochemical pathways, such as the 
synthesis of DNA accounting for the immunosuppressive effects of these 
drugs.5 These thiopurine drugs can undergo s-methylation by TPMT or 
oxidation to thiouric acid by xanthine oxidase to be inactivated (figure 1 ). 
Due to this alternative degradation pathway, the importance of the TPMT 
polymorphism is diminished in most tissues.6 However, hematopoietic 
tissues do not have measurable xanthine oxidase activity, leaving 
s-methylation as the major competing metabolic pathway.3 Patients who 
inherit TPMT deficiency accumulate excessive concentrations of the ac-
tive thioguanine nucleotides in blood cells. This causes a heightened lm-
munosuppressive reaction, leaving the patient at high risk for developing 
bone marrow toxicity, resulting in pancytopenia, a reduction in red blood 
cells, white blood cells and platelets. TPMT is not known to be involved 
in any pathway for endogenous substrates.4 
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Studies have been conducted to assess whether other genetic varia-
tions, aside from a TPMT polymorphism, affect azathioprine toxicity.7 
A study from the Department of Pharmacology at Pomeranian Medical 
University in Poland investigated the role of another enzyme, inosine 
triphosphate pyrophosphohydrolase (ITPA), which takes part further 
down the metabolic pathway of thiopurines. The goal of the study was 
to determine if azathioprine drug intolerance was related to ITPA allele 
variants. ITPA catalyzes the dephosphorylation of inosine triphosphate 
(ITP) to inosine monophosphate (IMP). A lack of ITPA leads to an 
excess of ITP, which has not been proven to be pathogenic. However, 
some researchers have noted that an accumulation of ITP during aza-
thioprine therapy can produce metabolites (such as thio-ITP), which may 
interfere with normal metabolic activity. The cohort study was conducted 
with a large group of renal transplant patients. Patients were evaluated 
for TPMT genetic polymorphisms and monitored for adverse effects of 
low white blood cell (WBC) count and hepatotoxicity. It was observed 
that ITPA had no effect on liver toxicity, and there was no statistical 
evidence that ITPA altered WBC count. Though previously determined 
in numerous other trials, the genetic effect of TPMT variations was 
confirmed yet again. Authors of the study concluded that genetic testing 
for ITPA during thioprine immunosuppressive therapy is not beneficial at 
this time because there is no statistical significance that it plays a role in 
adverse effects. 
ft also has been determined that 10-30 percent of patients cannot 
tolerate thiopurine therapy because of additional adverse events such 
as hepatotoxicity, pancreatitis, influenza-like symptoms and nausea.8 
A cohort study conducted in a small group of Greek pediatric patients 
diagnosed with inflammatory bowel disease (IBD) observed the relation-
ship between these adverse events and TPMT deficiency. A group of 
just under 100 children (mean age 11.5 years) undergoing treatment of 
IBD with thiopurine drugs was monitored for adverse events based on 
their genetic makeup in regards to their ability to metabolize TPMT. This 
study was conducted with the assumption that patients with a genetic 
variant that translates to poor TPMT activity experienced higher rates of 
the previously mentioned adverse events. Authors of the study conclud-
ed that, while dosages needed altering based on phenotype, the noted 
adverse events did not correlate with genetic variation. 
The TPMT genetic polymorphism serves as a good example of the 
importance of pharmacogenetics because it has been well characterized 
at the molecular, biochemical and clinical levels.4 The importance of this 
polymorphism is appreciated because its effect is highly penetrant when 
TMPT-deficient patients are treated with standard doses. This means 
that essentially 100 percent of TMPT-deficient patients will develop he-
matopoietic toxicity. Approximately 11 variant alleles have been associ-
ated with low TPMT enzymatic activity in humans. These alleles contain 
SNPs leading to amino acid substitutions, formation of a premature stop 
codon or destruction of a splice site. TPMT*3A is the most prevalent mu-
tant in whites while TPMT*C is the predominant mutant allele in Asian, 
African and African-American populations. 
Conclusion 
Polymerase chain reaction tests provide a means of prospectively 
identifying these patients prior to drug therapy, thereby minimizing tox-
icities.9 Although all studies have been done based on rough estimates, 
research points to the cost effectiveness of such testing by comparing 
it to the expected cost of treating extreme myelosuppression.10 It is 
estimated that, by predetermining a case of TPMT deficiency, nearly 
$3,000 could be saved in health care costs per patient. This data clearly 
shows that, aside from the lives that can be saved, genetic testing has 
an extremely positive impact from an economic standpoint. Even so, 
health care providers must remember that cautious monitoring of blood 
counts is required in all patients, since myelosuppression with thiopurine 
drugs can still occur in patients with normal TPMT activity.11 
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